Navigation Links
Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (OTCQB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the Actinium Pharmaceuticals' clinical programs and platform technology were presented in Vienna, Austria, at a technical meeting at the International Atomic Energy Agency (IAEA). The presentation was delivered by Dr. David Scheinberg, Interim Director of the Sloan-Kettering Institute, research division of the Memorial Sloan-Kettering Cancer Center.

"There is increasing interest in the uses of alpha particle therapy around the world," said Dr. Scheinberg. "We now see scientists, clinicians, isotope manufacturers, government agencies and commercial companies collaborating to enable therapeutic advances of these agents against cancer." 

Dr. Scheinberg's presentation focused on Actinium Pharmaceuticals' drug candidates Actimab-A and Bismab for acute myeloid leukemia as well as applications of alpha immunotherapy in treatment of solid cancers. The IAEA meeting at the United Nations headquarters in Vienna, Austria, was a closed workshop entitled "Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy".

About Actimab - A
Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium-225 and bismuth-213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which giv
'/>"/>

SOURCE Actinium Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
2. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
3. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
4. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
5. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
6. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
7. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Actinium Pharmaceuticals Announces New Round of Financing
11. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EVANSVILLE, Ind. , Sept. 16, 2014   ... builder of custom, automated assembly and test systems, recently ... for a leading medical device manufacturer. The Evana solution ... improve quality and ergonomics, as well as reduce labor. ... are automatically fed to Evana,s robotic assembly cell. The ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... 16, 2014  Synereca Pharmaceutics, Inc. (SPI), ... active drugs that restore or increase the ... $1.4 million convertible debt financing. Accele Venture ... accelerator Accele Biopharma, Inc., led the financing ... recognized private not-for-profit corporation focused on growing ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Council (NPC) today welcomed global specialty biopharmaceutical company Shire ... senior vice president, specialty pharma R&D, will serve as ... "The last few years have brought change ... important questions unresolved.  For the pharmaceutical industry, how ...
... Medical, Inc., a Minnesota-based medical device company, has announced that ... eripheral F acilitated A ntegrade S teering ... O cclusions (PFAST-CTOs) study.  The company received approval from ... US based IDE for the peripheral devices and is now ...
Cached Medicine Technology:National Pharmaceutical Council Welcomes Shire as Its Newest Member 2BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study 2
(Date:9/16/2014)... iFitDress.com, one of the most famous dress suppliers in the ... collection. According to the company’s sales manager, all these ... 69% off) at present. Additionally, all the company’s old clients ... frequent caller of your site. I like your products very ... happy. All items are of good quality. I sincerely want ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... routinely spot human papillomavirus (HPV), which is linked to the ... study shows that testing urine for HPV has good accuracy ... HPV," said lead researcher Dr. Neha Pathak. She is a ... Mary University of London, England. The test could be ...
(Date:9/16/2014)... September 16, 2014 These new programs allow ... years to receive up to $10,000 in a 0% interest ... well as other state and federal programs, are listed on ... paid back until you sell or move out of the ... 0% interest loan. There are no monthly payments paid by ...
(Date:9/16/2014)... A new study found that fractional flow ... true coronary bifurcation lesions yields similar outcomes to ... trial is the first study to compare FFR-guided ... today at the 26th annual Transcatheter Cardiovascular Therapeutics ... Foundation (CRF), TCT is the world,s premier educational ...
(Date:9/16/2014)... September 16, 2014 Programs and policies ... hundreds of billions of dollars in savings for the ... the Commonwealth Fund. To help spur these types of ... to 10 collaborative groups from across the country to ... http://bit.ly/1wo4gsa ) - a handbook designed to assist groups ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3
... Cancer (CoC) of the American College of Surgeons has granted ... Cancer Center as a result of surveys performed in 2010. ... to receive this award, is one of a select group ... country. Established in 2004, the CoC Outstanding Achievement ...
... , TUESDAY, April 26 (HealthDay News) -- The increased use ... and rapid angioplasty, has led to a decrease in deaths, ... a Swedish coronary care registry on more than 61,000 patients ... known as STEMI between 1996 and 2007. During those ...
... Sheikh Zayed Institute for Pediatric Surgical Innovation at ,Children,s ... has shown early promise as an option for chronic, severe ... bacterial infections, particularly sepsis. The study, which appears ... , sheds new light on the role of a pain ...
... for publication in The Endocrine Society,s Journal of Clinical ... white children with vitamin D deficiency both had higher fat ... of fat just under their skin and white children were ... internal organs. Studies in adults and children have shown ...
... needs a national pharmacare program and federal leaders must ... ( Canadian Medical Association Journal ) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.110643 ... and New Zealand, Canada lacks a national pharmacare program ... country. Currently, drugs that are covered in some provinces ...
... HealthDay Reporter , TUESDAY, April 26 (HealthDay News) -- ... the risk of developing Alzheimer,s disease, a new study ... to the house causes dementia, and other factors could ... the possible cost of isolation, said lead investigator Bryan ...
Cached Medicine News:Health News:Scott & White Glenda Vasicek Cancer Center receives national achievement award 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3Health News:Study: Resiniferatoxin may increase sepsis-related mortality 2Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Canadians should demand commitments for pharmacare program, says CMAJ 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 3
The K-ASSAY® D-Dimer Control set is intended to be used a consistent test sample of known concentration for monitoring the performance of D-Dimer immunoturbidimetric assays....
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
Medicine Products: